"COVID-19 vaccine" from_date:2012

COVID-19 Vaccine (Spikevax) (previously COVID-19 Vaccine Moderna) Spikevax (previously COVID-19 Vaccine Moderna) | European Medicines Agency (EMA)Skip to main contentSearchMain navigation * Medicines * Find medicine * Therapeutic areas: latest updates * Download medicine data * What we publish on medicines and when * Medicines under evaluation * National registers * Human regulatory * Overview programmes * History of EMA * Careers * Procurement * Glossaries * About this website * Data protection and privacy * Contacts 1. Home 2. Medicines 3. Spikevax (previously COVID-19 Vaccine Moderna) Spikevax (previously COVID-19 Vaccine Moderna)RSSAuthorisedThis medicine is authorised for use in the European Union COVID-19 mRNA vaccineMedicineHumanAuthorised Page contents * Overview * Product information

ffect of a 2- week interruption in methotrexate treatment on COVID- 19 vaccine response in people with immune- mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial Effect of a 2- week interruption in methotrexate treatment on COVID- 19 vaccine response in people with immune- mediated inflammatory diseases (VROOM study): a randomised, open label, superiority * Policies * FAQs * Contact us Close menu Efficacy and Mechanism Evaluation Effect of a 2- week interruption in methotrexate treatment on COVID- 19 vaccine response in people with immune- mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial 1. Journals Library 2. Efficacy and Mechanism Evaluation 3. Effect of a 2- week interruption in methotrexate treatment on COVID- 19

Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain Prescrire IN ENGLISH - Spotlight ''Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain'', 23 March 2021 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online International * Testimonials * Prescrire events * A global network Offers * Subscribe now * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) 1ANNEX ISUMMARY OF PRODUCT CHARACTERISTICSMedicinal product no longer authorised 2This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section4.8 for how to report adverse reactions.1.NAME separate doses of 0.5ml each. The second dose should be administered between 4 and 12weeks (28 to 84days) after the first dose (see section5.1).A booster dose(third dose)of 0.5ml may be given to individuals who completed the primary vaccinationcoursewith Vaxzevria oran mRNA COVID-19 vaccine (see sections4.8 and 5.1). The third dose should be administered at least 3 months after completingthe primary

Jcovden (previously COVID-19 Vaccine Janssen) Jcovden (previously COVID-19 Vaccine Janssen) | European Medicines Agency (EMA)Skip to main contentSearchMain navigation * Medicines * Find medicine * Therapeutic areas: latest updates * Download medicine data * What we publish on medicines and when * Medicines under evaluation * National registers * Human regulatory * Overview * Research * History of EMA * Careers * Procurement * Glossaries * About this website * Data protection and privacy * Contacts 1. Home 2. Medicines 3. Jcovden (previously COVID-19 Vaccine Janssen) Jcovden (previously COVID-19 Vaccine Janssen)RSSWithdrawnThis medicine's authorisation has been withdrawn COVID-19 vaccine (Ad26.COV2-S [recombinant])MedicineHumanWithdrawn Page contents * Overview * Product information

Guidance on COVID-19 vaccine booster doses: initial considerations for 2023

Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19

COVID-19 vaccine: Canadian immunization guide Skip to main contentSkip to "About government"Language selectionFrançais/ Gouvernement du CanadaSearchSearch Canada.caSearchMenuMAINMENU You are here:Canada.ca Health Healthy living Vaccines and immunization Canadian Immunization Guide Canadian Immunization Guide: Part 4 - Active VaccinesCOVID-19 vaccine: Canadian Immunization GuideFor health professionalsNoticeThis chapter has not yet been updated with the following statements from the National Advisory Committee on Immunization (NACI):October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 yearsOctober 7, 2022: Updated guidance on COVID-19 vaccine booster doses in CanadaSeptember 9, 2022: Updated guidance on COVID-19 vaccines

Patient Group Direction (PGD) for the administration of COVID-19 vaccines to individuals aged 5 years and over NHS England » Patient Group Direction (PGD) for the administration of COVID-19 vaccines to individuals aged 5 years and over Skip to main content Cookies on the NHS England websiteWe’ve put some small files called cookies on your device to make our site work. We’d also like to use Search Menu * About us * Our work * Commissioning * Get involved Patient Group Direction (PGD) for the administration of COVID-19 vaccines to individuals aged 5 years and overDocument first published: 7 March 2025 Page updated: 7 March 2025 Topic: Coronavirus, Vaccination Publication type: Guidance This Patient Group Direction (PGD) is for the administration of COVID-19 vaccines to eligible individuals

COVID-19 vaccine during pregnancy reduces risks to mother and baby COVID-19 vaccine during pregnancy reduces risks to mother and babyCOVID-19 vaccine during pregnancy reduces risks to mother and babySkip to content * Accessibility options: * * Search articles Evidence * About us * Browse content * Brain and Nerves * Birth Conditions * Blood * Cancer * Dementia * Detection, Screening and Diagnosis sign up * Contact us * Homepage * > * Alert * > * COVID-19 vaccine during pregnancy reduces risks to mother and baby COVID-19 vaccine during pregnancy reduces risks to mother and babyReproductive health and childbirth 27.02.25 doi: 10.3310/nihrevidence_66017 View commentaries and related content This is a plain English summary of an original research article. The views expressed are those

National protocol for COVID-19 vaccine (5 years and over) Skip to main contentCookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content from their services.Accept additional cookiesReject additional cookiesView cookies GOV.UK Navigation menu Menu Search GOV.UK HomeHealth and social carePublic healthHealth protectionImmunisationGuidanceNational protocol for COVID-19 mRNA vaccine (5 to 17 years of age)Protocol for the administration of COVID-19 mRNA vaccine to individuals aged 5 to 17 years in accordance with the national COVID-19 vaccination programme.From:UK Health Security AgencyPublished3

Safety of COVID-19 vaccines when given in pregnancy Safety of COVID-19 vaccines when given in pregnancy - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites to help us deliver content . Health and social care 3. Public health 4. Health protection 5. Immunisation Guidance Safety of COVID-19 vaccines when given in pregnancy Guidance for health professionals to share with pregnant women immunised with COVID-19 vaccines.From: UK Health Security Agency Published 18 December 2020 Last updated 30 April 2021 — See all updates Get emails about this page DocumentsThe safety of COVID-19

COVID-19 vaccination: information for healthcare practitioners COVID-19 vaccination: information for healthcare practitioners - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites account: sign in 1. Home 2. Health and social care 3. Public health 4. Health protection 5. Immunisation Guidance COVID-19 vaccination: information for healthcare practitioners Guidance for healthcare practitioners about the coronavirus (COVID-19) vaccination programme.From: UK Health Security Agency Published 27 November 2020 Last updated 10 March 2022 — See all updates Get emails about

COVID-19 Vaccine (recombinant, adjuvanted) - Bimervax Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. EMA/151429/2023 EMEA/H/C/006058 Bimervax (COVID-19 Vaccine (recombinant, adjuvanted)) An overview of Bimervax and why it is authorised in the EU What is Bimervax and what is it used for? Bimervax is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older. It can be used as a booster in people who have previously

Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta), as a booster Register online | Log in | My PrescrireISSUE CONTENTSTOPICSABOUT PRESCRIREOFFERSenglish.prescrire.org > Spotlight > 100 most recent > Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a boosterSpotlightEvery month, the subjects in Prescrire’s Spotlight.100 most recent :  1 | 10  | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90Spotlight100 most recentArchivesRecombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a booster COVID-19  The recombinant Beta variant covid-19 vaccine with AS03 adjuvant was authorised in the European Union in mid-November 2022, for use only as a booster in adults who have already received an mRNA or viral-vector vaccine.Full article (2

COVID-19 vaccine for children and adolescents: Technical report Skip to ContentA home for paediatricians. A voice for children and youth.POSITION STATEMENT6SharesCOVID-19 vaccine for children and adolescents: Technical reportPosted: Nov 24, 2023The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple

COVID-19 vaccination for children and young people This site uses cookies to store information on your computer.Some of these cookies are essential to make our site work. Others help give a better experience by getting insight into how the site is used, displaying embedded content and remembering preferences. You can read more about these on our cookies statement.I acceptI do not acceptNecessary to remember information that changes the way the website behaves or looks, like settings on an online tool.PreferencesOnOffCloseAbout this tool(Opens in a new window)Skip to main contentHomeResourcesCOVID-19 vaccination for children and young peopleHealth Policy teamThe Joint Committee on Vaccination and Immunisation and the Chief Medical Officers have been advising on when COVID-19 vaccinations should

What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern v21 COVID-19 Living Evidence Synthesis # 8 (Version 8.21: 20 Feb 2023) Question What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern? Findings For vaccine effectiveness in variants of concern (VOC), we present to 40.8]- 1 Obs [39]) in children age 3 to 11 years o We have low certainty evidence that 2 doses of Sinopharm (BBIBP-CorV) did not reach threshold for protection from death from VOC Omicron BA.1 (66.9% [95% CI, 6.4 to 89.8]- 1 Obs [39]) in children age 3 to 11 years 6 Table 1: Visual summary of evidence for COVID-19 vaccines for variants of concern (up to 28 days after 2 doses

COVID-19 Living Evidence Synthesis 8 - What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern (Version 20) COVID-19 Living Evidence Synthesis # 8 (Version 8.20: 17 Jan 2023) Question What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern? Findings For vaccine age 3 to 11 years 6 Table 1: Visual summary of evidence for COVID-19 vaccines for variants of concern (up to 28 days after 2 doses) Percentages indicate level of effectiveness from 0% (no effect) to 100% (full protection): ranges of estimated means are provided when ≥ 1 study is available; estimated mean value is provided for single studies Colour indicates level of certainty based

COVID-19 vaccine effectiveness in unvaccinated moderate to severely immunocompromised people with a previous infection 1 Rapid Evidence Synthesis: COVID-19 Vaccine Effectiveness in Unvaccinated Moderate to Severely Immunocompromised People with a Previous Infection Date of Literature Search: August 11, 2023 Date of Revision: Sept 14, 2023 Date of Submission: August 28, 2023 Prepared .................................................................................................................................................... 23 3 EXECUTIVE SUMMARY Objectives: To identify the available evidence on the benefit of one vs. two or more doses of COVID-19 vaccine in the vaccine schedule (i.e., primary series) for unvaccinated individuals at high risk of severe illness due to COVID-19 who have been previously infected with SARS-CoV-2. Design: Rapid evidence synthesis Methods: Two independent reviewers assessed fu..